The CD274 Knockout HeLa Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the CD274 gene. This heterogeneous cell pool provides a robust loss-of-function model for studying PD-L1 biology without requiring single-cell cloning. The polyclonal format preserves genetic diversity while ensuring effective gene knockout at the population level, making it suitable for diverse experimental contexts.
HeLa cells are an immortalized human epithelial cell line originally derived from cervical adenocarcinoma and harbor HPV18 genomic integration. They exhibit extensive chromosomal abnormalities and rapid proliferation, rendering them a versatile platform for cancer research. The well-characterized nature of HeLa cells facilitates reproducible experimental manipulation and compatibility with standardized protocols across molecular and cellular biology studies.
CD274 encodes PD-L1, a transmembrane immune checkpoint ligand that engages PD-1 on T cells to attenuate antitumor immunity. PD-L1 binding to PD-1 triggers recruitment of the phosphatase SHP2, which dephosphorylates proximal TCR signaling molecules such as ZAP70 and LCK. This cascade suppresses downstream PI3K-AKT and ERK pathways, diminishing T-cell proliferation, IL-2 and IFN-?? secretion, and cytotoxicity. PD-L1 expression is transcriptionally regulated by inflammatory signals such as interferon-gamma (IFNG) through the JAK-STAT pathway, with STAT1 and STAT3 activating the CD274 promoter. Additional regulators include NF-kB, MYC, HIF1A, and EGFR signaling. On the membrane, PD-L1 stability and trafficking are regulated by association with the CMTM6 and CMTM4 proteins.
In the HeLa cellular context, CD274 knockout eliminates PD-L1 surface expression, enabling researchers to dissect its role in immune evasion without interference from endogenous PD-L1. HeLa cells endogenously express PD-L1 at variable levels and can be stimulated with IFN-?? to upregulate the ligand, making them a relevant model for studying intrinsic and adaptive immune resistance. The knockout population serves as an isogenic negative control for antibody validation, small-molecule inhibitor studies, and functional assays assessing T-cell engagement.
This knockout product is ideally suited for investigating PD-1/PD-L1 signaling mechanisms, evaluating PD-L1 inhibitors, and exploring tumor immune evasion strategies. Typical experiments include flow cytometry to confirm PD-L1 loss, co-culture with T cells to measure restoration of cytokine production and cytotoxicity, and western blotting to analyze downstream signaling effectors such as phosphorylated AKT and ERK. Additionally, the cells provide a reliable platform for siRNA or CRISPR rescue experiments to validate genotype-phenotype relationships. For technical inquiries or personalized support, researchers are encouraged to contact Ascent Research.
